CN117665295A - 一种兽用五分类血细胞检测试剂及制备方法 - Google Patents
一种兽用五分类血细胞检测试剂及制备方法 Download PDFInfo
- Publication number
- CN117665295A CN117665295A CN202311644489.1A CN202311644489A CN117665295A CN 117665295 A CN117665295 A CN 117665295A CN 202311644489 A CN202311644489 A CN 202311644489A CN 117665295 A CN117665295 A CN 117665295A
- Authority
- CN
- China
- Prior art keywords
- buffer solution
- blood cell
- hemolytic agent
- preservative
- tris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000601 blood cell Anatomy 0.000 title claims abstract description 44
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 31
- 238000001514 detection method Methods 0.000 title claims abstract description 30
- 244000144972 livestock Species 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 239000003219 hemolytic agent Substances 0.000 claims abstract description 55
- 239000003085 diluting agent Substances 0.000 claims abstract description 32
- 239000007853 buffer solution Substances 0.000 claims abstract description 31
- 239000003755 preservative agent Substances 0.000 claims abstract description 25
- 230000002335 preservative effect Effects 0.000 claims abstract description 25
- 241001465754 Metazoa Species 0.000 claims abstract description 24
- 239000003093 cationic surfactant Substances 0.000 claims abstract description 17
- 238000012360 testing method Methods 0.000 claims abstract description 16
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 11
- 230000003204 osmotic effect Effects 0.000 claims abstract description 11
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 8
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 30
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- 239000000872 buffer Substances 0.000 claims description 22
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 claims description 13
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 10
- 235000006408 oxalic acid Nutrition 0.000 claims description 10
- 239000001509 sodium citrate Substances 0.000 claims description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 9
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 claims description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 7
- 235000011152 sodium sulphate Nutrition 0.000 claims description 7
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 6
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 5
- DEQXHPXOGUSHDX-UHFFFAOYSA-N methylaminomethanetriol;hydrochloride Chemical compound Cl.CNC(O)(O)O DEQXHPXOGUSHDX-UHFFFAOYSA-N 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 4
- 229930182566 Gentamicin Natural products 0.000 claims description 4
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 claims description 4
- 229960002518 gentamicin Drugs 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 3
- 229940113115 polyethylene glycol 200 Drugs 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 abstract description 34
- 238000004458 analytical method Methods 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 210000003743 erythrocyte Anatomy 0.000 description 41
- 102000001554 Hemoglobins Human genes 0.000 description 38
- 108010054147 Hemoglobins Proteins 0.000 description 38
- 210000001772 blood platelet Anatomy 0.000 description 29
- 238000005534 hematocrit Methods 0.000 description 28
- 210000000440 neutrophil Anatomy 0.000 description 26
- 239000000523 sample Substances 0.000 description 21
- 238000002156 mixing Methods 0.000 description 16
- 238000001914 filtration Methods 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 239000002994 raw material Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000005303 weighing Methods 0.000 description 15
- 238000005259 measurement Methods 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 241000282465 Canis Species 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000003651 basophil Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012470 diluted sample Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- NYWPTMUTCHMGDH-UHFFFAOYSA-L S(=O)(=O)([O-])[O-].[Na+].N1=CC=CC=C1.[Na+] Chemical compound S(=O)(=O)([O-])[O-].[Na+].N1=CC=CC=C1.[Na+] NYWPTMUTCHMGDH-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000004697 chelate complex Chemical class 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- XNRNJIIJLOFJEK-UHFFFAOYSA-N sodium;1-oxidopyridine-2-thione Chemical compound [Na+].[O-]N1C=CC=CC1=S XNRNJIIJLOFJEK-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Abstract
本发明提供一种兽用五分类血细胞检测试剂，包括：稀释液、第一溶血剂和第二溶血剂；所述稀释液包括：第一缓冲液50～100 mmol/L、渗透压调节剂2.2～6.2 g/L、抗凝剂0.05～0.5 g/L、第一防腐剂0.025～0.5 g/L；所述第一溶血剂包括：非离子表面活性剂0.05～2 g/L、第一阳离子表面活性剂0.05～6.75 g/L、第二缓冲液50～100 mmol/L和第二防腐剂0.02～1 g/L；所述第二溶血剂包括：第二阳离子表面活性剂0.2～10 g/L、第三缓冲液50～100 mmol/L和第三防腐剂0.02～0.5 g/L。本发明提供的兽用五分类血细胞检测试剂配制工艺简单，易于生产，有利于降低成本；试剂稳定性好，测试更加精确，具有良好的推广应用价值。本发明对比三分群兽用血细胞分析中白细胞的分类更加精确，对于判断感染种类更具有针对性。
Description
技术领域
本发明属于生化分析技术领域，具体涉及一种兽用五分类血细胞检测试剂及制备方法。
背景技术
动物血常规检验是指对动物血液中有形成分如红细胞、白细胞、血小板等指标进行质和量的分析，也是为动物血液病及相关系统疾病的诊断和鉴别提供重要信息的途径之一。在动物健康的情况下，三大常规值都处于正常范围，但是当患了疾病，或身体受到某种不良刺激和创伤时，其正常值就会发生变化。
临床上采用血细胞分析仪进行血常规的检测，不同的血细胞分析仪存在对应的检测试剂配套使用。通常认为人用血细胞分析仪和兽用血细胞分析仪可以共用仪器和试剂，然而，由于人体血液细胞和动物血液细胞存在差别，尤其是在红细胞的体积和白细胞的分类组成上，例如，很多动物的红细胞有核，人血红细胞有核的很少，因此不能直接采用人血的分析技术对动物血液进行检测。目前，兽用血细胞的检测主要是三分群检测，然而，三分群对血细胞的分类项目较少，给临床分析带来不便，因此亟需提供一种兽用五分类血细胞检测试剂，供临床检测血细胞计数、血红蛋白含量和血细胞分类等。
发明内容
本发明公开了一种兽用五分类血细胞检测试剂及制备方法，以解决现有技术中兽用三分群血细胞检测对血细胞的分类项目较少的问题。
本申请提供一种兽用五分类血细胞检测试剂，包括：稀释液、第一溶血剂和第二溶血剂；
所述稀释液包括：第一缓冲液50～100 mmol/L、渗透压调节剂2.2～6.2 g/L、抗凝剂0.05～0.5 g/L、第一防腐剂0.025～0.5 g/L；
所述第一溶血剂包括：非离子表面活性剂0.05～2 g/L、第一阳离子表面活性剂0.05～6.75 g/L、第二缓冲液50～100 mmol/L和第二防腐剂0.02～1 g/L；
所述第二溶血剂包括：第二阳离子表面活性剂0.2～10 g/L、第三缓冲液50～100mmol/L和第三防腐剂0.02～0.5 g/L。
可选的，所述第一缓冲液为Tris-Tris盐酸盐缓冲液，所述Tris-Tris盐酸盐缓冲液包括三羟甲基氨基甲烷和三羟甲基氨基甲烷盐酸盐。
可选的，所述渗透压调节剂为氯化钠、氯化钾、硫酸钠中的至少一种。
可选的，所述抗凝剂为EDTA·2K、EDTA·2Na、枸橼酸钠中的至少一种。
可选的，所述第一防腐剂为Proclin150、Proclin300、庆大霉素、BIT-10、SPT中的至少一种。
可选的，所述非离子表面活性剂为AEO-10、吐温60、吐温80和聚乙二醇200中的至少一种；所述第一阳离子表面活性剂为十二烷基三甲基溴化铵、十六烷基三甲基氯化铵中的至少一种。
可选的，所述第二缓冲液为柠檬酸和柠檬酸钠或者柠檬酸和磷酸氢二钠。
可选的，所述第二防腐剂为甲醇或者Proclin300，所述第三防腐剂为甲醇。
可选的，所述第二阳离子表面活性剂为十二烷基三甲基氯化铵、十六烷基三甲基氯化铵、十二烷基三甲基溴化铵、十六烷基三甲基溴化铵中的至少一种。
可选的，所述第三缓冲液为草酸和草酸钾或者草酸和磷酸氢二钾。
本发明提供的兽用五分类血细胞检测试剂包括稀释液、第一溶血剂和第二溶血剂，组分简单，有利于环境保护；配制工艺简单，易于生产，有利于降低成本；试剂稳定性好，测试更加精确，具有良好的推广应用价值。本发明填充了对兽用血细胞的自动化分析研究较少的空白，且对比三分群兽用血细胞分析中白细胞的分类更加精确，对于判断感染种类更具有针对性。
实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动下所获得的所有其他实施例，都属于本发明保护的范围。
本申请提供一种兽用五分类血细胞检测试剂，包括：稀释液、第一溶血剂和第二溶血剂；所述稀释液包括：第一缓冲液50～100 mmol/L、渗透压调节剂2.2～6.2 g/L、抗凝剂0.05～0.5 g/L、第一防腐剂0.025～0.5 g/L；所述第一溶血剂包括：非离子表面活性剂0.05～2 g/L、第一阳离子表面活性剂0.05～6.75 g/L、第二缓冲液50～100 mmol/L和第二防腐剂0.02～1 g/L；所述第二溶血剂包括：第二阳离子表面活性剂0.2～10 g/L、第三缓冲液50～100 mmol/L和第三防腐剂0.02～0.5 g/L。
本发明提供的兽用五分类血细胞检测试剂包括稀释液、第一溶血剂和第二溶血剂，组分简单，有利于环境保护；配制工艺简单，易于生产，有利于降低成本；试剂稳定性好，测试更加精确，具有良好的推广应用价值。本发明填充了对兽用血细胞的自动化分析研究较少的空白，且对比三分群兽用血细胞分析中白细胞的分类更加精确，对于判断感染种类更具有针对性。
可选的，所述第一缓冲液为Tris-Tris盐酸盐缓冲液，所述Tris-Tris盐酸盐缓冲液包括三羟甲基氨基甲烷和三羟甲基氨基甲烷盐酸盐。第一缓冲液用于维持稀释液pH值，使得稀释液的pH值维持在6.8～7.8，具有一定的酸碱缓冲作用。
可选的，所述渗透压调节剂为氯化钠、氯化钾、硫酸钠中的至少一种。渗透压调节剂为能够调节稀释液具有适当的离子强度和电导率，适当的离子强度能在一定时间内完整地保持血细胞原来的体积，而合适的电导率能保证获得与细胞体积相应的脉冲大小，保证测量结果准确。
可选的，所述抗凝剂为EDTA·2K、EDTA·2Na、枸橼酸钠中的至少一种。抗凝剂能与血液中Ca2+结合成螯合物，凝血过程被阻断，血液不能发生凝固。
可选的，所述第一防腐剂为Proclin150、Proclin300、庆大霉素、BIT-10、SPT（Sodium Pyrithione,吡啶硫酸钠）中的至少一种。在稀释液中加入防腐剂既有防腐抑菌作用，还具有抑制细胞表面酶活性从而降低细胞活性的作用，从而可以较好的保护细胞，使其测试更准确。
可选的，所述非离子表面活性剂为AEO-10、吐温60、吐温80、聚乙二醇200中的至少一种，所述第一阳离子表面活性剂为十二烷基三甲基溴化铵、十六烷基三甲基氯化铵中的至少一种。采用第一阳离子表面活性剂和非离子表面活性剂的搭配使用，利用非离子表面活性剂具有良好的清洗功能，不影响测试的情况下可以较好的避免样本间的交叉污染。
可选的，所述第二缓冲液为柠檬酸和柠檬酸钠或者柠檬酸和磷酸氢二钠。第二缓冲液能够维持第一溶血剂的pH相对稳定。
可选的，所述第二防腐剂为甲醇或者Proclin300。第二防腐剂具有广谱活性、优越的兼容性和稳定性及在使用浓度下的低毒性，从而延长产品的储存时间；所述第三防腐剂为甲醇。
可选的，所述第二阳离子表面活性剂为十二烷基三甲基氯化铵、十六烷基三甲基氯化铵、十二烷基三甲基溴化铵、十六烷基三甲基溴化铵中的至少一种。本申请提供的第二阳离子表面活性剂具有良好的溶血能力，能够溶解红细胞，通过红细胞的溶解来释放血红蛋白，形成稳定的血红蛋白衍生物，进行血红蛋白测试，且季铵盐型表面活性剂还具有抑菌功能。实际应用中，通常选择至少两种第二阳离子表面活性剂搭配使用，利用其中一种阳离子表面活性剂，例如十二烷基三甲基溴化铵溶解红细胞，利用另一种阳离子表面活性剂，例如十六烷基三甲基氯化铵和血红蛋白结合形成衍生物，进而对血红蛋白和白细胞嗜碱性粒细胞进行测试。
可选的，所述第三缓冲液为草酸和草酸钾或者草酸和磷酸氢二钾。正常动脉血pH值为7.35～7.45，呈弱碱性，酸性条件下更有利于细胞的溶解。
本申请提供的第二溶血剂中，采用甲醇作为防腐剂，甲醇具有低毒性，不仅有防腐的功能，还有利于形成的血红蛋白衍生物的稳定，从而提高血红蛋白测试的准确性。
本申请提供的兽用五分类血细胞检测试剂的制备方法包括以下步骤：
步骤a，配制稀释液：按照本申请提供的稀释液配方称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
步骤b，配制第一溶血剂Vet-DIFF：按照本申请提供的第一溶血剂的配方称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
步骤c，配制第二溶血剂Vet-LH：按照本申请提供的第二溶血剂的配方称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
本申请提供的兽用五分类血细胞检测试剂的使用方法说明如下：首先，将稀释液与待测样本混合，获得稀释后的待测样本；其次，取一定量稀释后的待测样本加入第一溶血剂，第一溶血剂中的表面活性剂能够溶解红细胞，便于白细胞的分类与计数；再次，另取一定量稀释后的待测样本加入第二溶血剂，进行血红蛋白测试。
以下通过具体实施例对本申请进一步详细说明。
实施例
（1）稀释液的组分和含量：Tris-Tris盐酸盐缓冲液50 mmol/L（pH 7.2），氯化钾1.1 g/L、硫酸钠1.1 g/L，EDTA·2Na 0.05 g/L，Proclin300 0.025 g/L；所述Tris-Tris盐酸盐缓冲液为三羟甲基氨基甲烷和三羟甲基氨基甲烷盐酸盐（Tris-Tris盐酸盐缓冲液中组分的配比由其pH值而定）；
稀释液的配制：按照上述配方中的成分称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
（2）第一溶血剂Vet-DIFF的组分和含量：吐温80 0.05 g/L、十二烷基三甲基溴化铵0.05 g/L、第二缓冲液50 mmol/L（pH 4.0）和甲醇 0.02 g/L，所述第二缓冲液为柠檬酸和柠檬酸钠；
第一溶血剂Vet-DIFF的配制：按照上述配方中的成分称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
（3）第二溶血剂Vet-LH的组分和含量：十六烷基三甲基氯化铵0.1 g/L、十二烷基三甲基溴化铵0.1 g/L、第三缓冲液50 mmol/L（pH 2.0）和甲醇0.02 g/L，所述第三缓冲液为草酸和磷酸氢二钾；
第二溶血剂Vet-LH的配制：按照上述配方中的成分称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
实施例
（1）稀释液的组分和含量：Tris-Tris盐酸盐缓冲液75 mmol/L（pH 7.2），氯化钾2.2 g/L、硫酸钠2.2 g/L，枸橼酸钠0.25 g/L，Proclin150 0.05 g/L，SPT0.02 g/L；所述Tris-Tris盐酸盐缓冲液为三羟甲基氨基甲烷和三羟甲基氨基甲烷盐酸盐；
稀释液的配制：按照上述配方中的成分称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
（2）第一溶血剂Vet-DIFF的组分和含量：聚乙二醇200 0.5 g/L、十二烷基三甲基溴化铵4.55 g/L、十六烷基三甲基氯化铵2.2 g/L、第二缓冲液75mmol/L（pH 4.0）和Proclin300 0.5 g/L，所述第二缓冲液为柠檬酸和柠檬酸钠；
第一溶血剂Vet-DIFF的配制：按照上述配方中的成分称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
（3）第二溶血剂Vet-LH的组分和含量：十二烷基三甲基氯化铵2.67 g/L、十二烷基三甲基溴化铵2.55 g/L、十六烷基三甲基溴化铵0.75 g/L、缓冲液75 mmol/L（pH 2.0）和甲醇0.25 g/L，所述缓冲液为草酸和磷酸氢二钾；
第二溶血剂Vet-LH的配制：按照上述配方中的成分称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
实施例
（1）稀释液的组分和含量：Tris-Tris盐酸盐缓冲液100 mmol/L（pH 7.2），氯化钠4.2 g/L、硫酸钠2.0 g/L，EDTA·2K 0.5 g/L，庆大霉素 0.25 g/L，BIT-10 0.25 g/L；所述Tris-Tris盐酸盐缓冲液为羟甲基氨基甲烷和三羟甲基氨基甲烷盐酸盐；
稀释液的配制：按照上述配方中的成分称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
（2）第一溶血剂Vet-DIFF的组分和含量：吐温60 1.0 g/L、AEO-10 1.0 g/L、十二烷基三甲基氯化铵 6.0 g/L、第二缓冲液100 mmol/L（pH 4.0）和Proclin300 1.0 g/L，所述第二缓冲液为柠檬酸和磷酸氢二钠；
第一溶血剂Vet-DIFF的配制：按照上述配方中的成分称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
（3）第二溶血剂Vet-LH的组分和含量：十二烷基三甲基氯化铵7.5 g/L、十六烷基三甲基溴化铵2.5 g/L、第三缓冲液100 mmol/L（pH 2.0）和甲醇0.5 g/L，所述第三缓冲液为草酸和草酸钾；
第二溶血剂Vet-LH的配制：按照上述配方中的成分称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
（1）稀释液的组分和含量：磷酸盐缓冲液100 mmol/L（pH 7.2），氯化钠8.2 g/L、硫酸钠3.19 g/L，EDTA·2K 0.5 g/L，SPT 0.5 g/L；所述磷酸盐缓冲液为十二水合磷酸氢二钠和磷酸二氢钠。
稀释液的配制：按照上述配方中的成分称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
（2）第一溶血剂Vet-DIFF的组分和含量：聚乙二醇2.0 g/L、吐温80 1.8 g/L、第二缓冲液100 mmol/L（pH 4.0）和Proclin300 1.0 g/L，所述第二缓冲液为柠檬酸和磷酸氢二钠；
第一溶血剂Vet-DIFF的配制：按照上述配方中的成分称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
（3）第二溶血剂Vet-LH的组分和含量：十六烷基三甲基氯化铵2.0 g/L、十六烷基三甲基溴化铵0.5 g/L、第三缓冲液50 mmol/L（pH 2.0）和甲醇0.6 g/L，所述第三缓冲液为草酸和磷酸氢二钾；
第二溶血剂Vet-LH的配制：按照上述配方中的成分称取各原料，加水溶解混匀，放置室温，摇匀，0.22um滤膜过滤即得。
用布拉泽BHA-5000Vet血细胞分析仪测试上述实施例1~3以及对比例1的稀释液、第一溶血剂Vet-DIFF和第二溶血剂Vet-LH。首先吸取样本，吸取样本后，加入稀释液稀释，在红细胞池进行红细胞和血小板计数，加入第一溶血剂Vet-DIFF在白细胞池进行白细胞四分类，再加入第二溶血剂Vet-LH进行血红蛋白和嗜碱性粒细胞检测。
本申请利用CV值（Coeffcient of Variance，标准差与均值的比率即变异系数）和相对偏差对检测结果进行分析，其中， CV值用于反映变量的离散程度，CV值越小，表示检测的灵敏度越高；相对偏差指某一次测量的绝对偏差占平均值的百分比，用于衡量单项测定结果对平均值的偏离程度，相对偏差越小，表明测定结果的随机误差越小，即分析结果的准确度越高。
测定方法如下：开机自检后，取30支新鲜全血标本，其中包括猫科样本10支、犬科样本10支、马样本10支，分别测定CV值以及相对偏差。具体计算方法为：每个样本测定10次，利用10次测定结果的标准差与均值的比率作为CV值。另外，每个样本检测3次，与市场成熟迈瑞兽用五分类血细胞分析仪测值进行对比，计算相对偏差；计算公式如下：相对偏差B%=（Xi-T）/T*100%，其中，Xi为检测值，T为迈瑞兽用五分类血细胞分析仪测值；记录3次检测结果的相对偏差的平均值。
本申请中，主要测定红细胞（RBC）、白细胞（WBC）、淋巴细胞（LYM）、中性粒细胞（NEU）、嗜酸性粒细胞（EOS）、嗜碱性粒细胞（BAS）、单核细胞（MON）、红细胞（RBC）、血红蛋白（HGB）、红细胞压积（HCT）、平均红细胞体积（MCV）、血小板（PLT），上述实施例及对比例分别按照以上规定检测，分别进行CV值比较和相对偏差比较，对比结果如表1～表8所示。
表1 实施例1测值CV值
| 猫科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 2.17% | -0.24% | -3.58% | -1.99% | -1.32% | 0.31% | -2.12% | 2.18% | 0.87% | 1.58% |
| NEU# | 1.07% | 0.73% | -1.27% | 0.59% | -0.07% | 1.06% | 0.83% | 1.28% | -0.20% | 2.00% |
| Lym# | 0.20% | -0.41% | 0.27% | 1.16% | 1.97% | 0.19% | 1.69% | 1.16% | -1.22% | 1.16% |
| Mon# | 1.72% | 1.37% | -0.55% | 1.52% | 1.59% | 1.46% | 1.11% | 2.95% | 1.02% | 2.41% |
| Eos# | 0.62% | 0.63% | 0.74% | 0.90% | 1.73% | 0.45% | 0.28% | 1.60% | 1.17% | 0.42% |
| Bas# | 2.30% | -2.70% | -0.69% | -4.82% | -1.08% | -1.33% | -4.08% | -0.15% | 1.45% | 1.91% |
| RBC | -2.59% | 0.18% | -3.35% | -1.09% | -3.19% | 0.53% | -0.58% | 0.53% | -3.23% | 3.35% |
| HGB | -0.42% | 2.05% | -0.80% | -0.97% | -2.25% | 0.96% | -1.85% | 0.19% | -0.57% | -2.27% |
| HCT | -0.23% | 1.74% | 0.91% | -0.46% | -1.01% | 0.60% | -1.58% | 0.67% | -0.53% | -1.33% |
| MCV | -1.24% | 1.66% | -0.20% | -0.28% | -2.06% | 1.80% | -1.58% | 0.75% | 0.75% | -1.62% |
| PLT | -2.40% | -4.51% | -3.07% | -0.14% | 0.20% | -2.67% | -2.39% | -0.53% | 0.12% | -1.16% |
| 犬科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | -0.29% | -2.48% | 1.76% | -0.99% | 1.16% | 2.45% | 1.39% | 0.20% | 1.12% | 0.80% |
| NEU# | -1.50% | -2.60% | 2.79% | -0.50% | 1.24% | 3.09% | 3.38% | 0.49% | 0.41% | 0.56% |
| Lym# | 0.24% | -0.27% | -1.19% | -3.39% | 0.38% | 4.92% | 2.30% | 0.73% | 1.00% | 0.81% |
| Mon# | 0.60% | -1.55% | 0.00% | 0.00% | 1.27% | 0.00% | 3.73% | 2.71% | 1.11% | 0.21% |
| Eos# | -1.16% | -0.45% | 0.95% | 2.08% | 1.26% | 1.66% | 2.54% | 4.13% | 3.98% | 0.62% |
| Bas# | 0.00% | 0.00% | -2.74% | 4.05% | 2.58% | 5.20% | 0.00% | 5.52% | 0.00% | 0.66% |
| RBC | 1.52% | -0.70% | 0.00% | 3.21% | -3.19% | 1.37% | 1.94% | -2.06% | 1.25% | 2.64% |
| HGB | -0.72% | -0.27% | 1.50% | 0.00% | -2.25% | 0.56% | 2.12% | 4.07% | 2.66% | -2.27% |
| HCT | -1.08% | -2.16% | 0.47% | 2.71% | -1.01% | 1.50% | 1.08% | 3.31% | 3.21% | -3.19% |
| MCV | -5.11% | -0.89% | 1.02% | 3.22% | -2.06% | 0.51% | 0.73% | 0.91% | 0.74% | -2.25% |
| PLT | -1.86% | 3.89% | -0.40% | 1.09% | 0.20% | 1.28% | 1.19% | 0.50% | 1.36% | -1.16% |
| 马样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 2.85% | 3.55% | 1.13% | 1.71% | 0.16% | 1.54% | 1.86% | 1.46% | 3.26% | 2.68% |
| NEU# | 2.09% | 2.59% | 1.52% | 0.97% | 2.11% | 1.49% | 2.57% | 0.87% | 3.42% | 1.48% |
| Lym# | 0.72% | 0.12% | 1.78% | 3.37% | 0.58% | 0.21% | 2.67% | 2.29% | 2.32% | 1.69% |
| Mon# | 2.86% | 3.11% | 1.10% | 0.98% | 1.91% | 2.26% | 1.35% | 0.91% | 3.11% | 1.48% |
| Eos# | 1.66% | 1.69% | 1.43% | 2.05% | 3.15% | 0.85% | 1.44% | 0.73% | 0.87% | 1.29% |
| Bas# | 3.37% | 3.42% | 2.50% | 0.15% | 1.51% | 3.35% | 2.38% | 2.38% | 3.24% | 1.90% |
| RBC | 2.57% | 1.42% | 1.67% | 0.37% | 0.65% | 0.12% | 2.72% | 2.10% | 2.54% | 2.63% |
| HGB | 1.08% | 3.50% | 2.50% | 0.59% | 2.80% | 0.99% | 3.50% | 2.54% | 2.23% | 1.12% |
| HCT | 2.85% | 2.71% | 2.91% | 3.04% | 0.22% | 0.51% | 1.41% | 1.12% | 1.38% | 1.83% |
| MCV | 2.60% | 0.66% | 2.79% | 2.27% | 2.60% | 2.38% | 2.12% | 0.69% | 0.74% | 2.40% |
| PLT | 0.59% | 3.19% | 1.61% | 0.56% | 3.19% | 1.02% | 2.61% | 2.91% | 0.98% | 2.90% |
表2 实施例1测值准确性相对偏差
| 猫科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 3.62% | 3.74% | 1.94% | 2.06% | 0.85% | 1.66% | 1.62% | 1.43% | 0.63% | 3.11% |
| NEU# | 3.55% | 3.82% | 1.05% | 1.32% | 1.05% | 2.42% | 3.61% | 2.08% | 2.73% | 1.81% |
| Lym# | 2.80% | 2.84% | 1.61% | 3.95% | 2.78% | 1.53% | 3.21% | 1.92% | 3.57% | 2.50% |
| Mon# | 3.97% | 2.75% | 0.95% | 1.10% | 2.61% | 1.34% | 2.11% | 3.10% | 1.53% | 3.59% |
| Eos# | 3.91% | 1.43% | 2.77% | 1.11% | 1.65% | 3.43% | 1.52% | 3.23% | 1.32% | 1.87% |
| Bas# | 2.44% | 1.75% | 3.70% | 1.00% | 3.38% | 1.03% | 2.95% | 3.43% | 1.61% | 1.61% |
| RBC | 1.39% | 2.19% | 1.82% | 2.88% | 1.33% | 2.39% | 1.25% | 0.52% | 1.21% | 2.73% |
| HGB | 2.97% | 0.95% | 3.32% | 1.68% | 3.19% | 0.52% | 0.73% | 2.90% | 2.57% | 1.92% |
| HCT | 1.63% | 2.05% | 0.93% | 1.81% | 2.83% | 1.39% | 0.60% | 2.29% | 2.41% | 2.85% |
| MCV | 1.32% | 1.29% | 3.30% | 1.69% | 0.92% | 1.42% | 2.75% | 1.65% | 0.77% | 2.75% |
| PLT | 3.98% | 2.66% | 2.19% | 0.71% | 3.47% | 1.57% | 3.79% | 2.33% | 3.93% | 3.15% |
| 犬科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 2.45% | 1.11% | 0.94% | 2.91% | 0.67% | 1.03% | 1.05% | 2.75% | 1.77% | 1.80% |
| NEU# | 2.79% | 1.70% | 2.14% | 3.46% | 3.20% | 2.57% | 2.72% | 3.70% | 1.30% | 3.03% |
| Lym# | 2.72% | 0.85% | 2.45% | 1.79% | 2.27% | 1.99% | 2.49% | 2.67% | 3.07% | 3.05% |
| Mon# | 2.92% | 1.98% | 1.27% | 3.08% | 2.10% | 2.17% | 3.39% | 1.63% | 3.38% | 3.46% |
| Eos# | 1.83% | 3.77% | 1.59% | 0.98% | 3.91% | 0.94% | 1.20% | 2.24% | 2.08% | 1.53% |
| Bas# | 1.14% | 1.02% | 1.37% | 1.21% | 2.68% | 1.73% | 2.82% | 2.36% | 2.17% | 2.67% |
| RBC | 1.51% | 2.62% | 2.41% | 1.71% | 1.81% | 2.49% | 1.47% | 2.36% | 1.53% | 1.51% |
| HGB | 0.62% | 2.89% | 1.88% | 3.10% | 1.77% | 1.77% | 3.26% | 3.24% | 3.14% | 1.50% |
| HCT | 2.37% | 0.83% | 1.89% | 2.50% | 0.83% | 1.59% | 1.51% | 1.57% | 2.62% | 1.11% |
| MCV | 1.06% | 1.74% | 3.97% | 2.10% | 1.45% | 2.29% | 0.92% | 2.06% | 1.73% | 0.46% |
| PLT | 0.85% | 1.32% | 1.54% | 0.54% | 1.23% | 1.74% | 3.49% | 3.56% | 3.78% | 2.70% |
| 马样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 2.06% | 1.18% | 1.05% | 1.63% | 2.44% | 0.84% | 1.97% | 0.64% | 0.89% | 2.16% |
| NEU# | 2.11% | 3.10% | 0.90% | 2.36% | 1.16% | 2.20% | 1.59% | 0.56% | 3.07% | 1.95% |
| Lym# | 1.61% | 3.07% | 1.48% | 1.77% | 3.53% | 0.97% | 0.69% | 1.95% | 1.15% | 3.86% |
| Mon# | 3.79% | 2.92% | 1.22% | 2.63% | 2.11% | 3.32% | 3.75% | 2.34% | 1.45% | 1.17% |
| Eos# | 1.44% | 3.06% | 2.75% | 1.80% | 3.21% | 3.91% | 1.66% | 2.33% | 1.48% | 2.37% |
| Bas# | 1.96% | 1.07% | 2.48% | 1.47% | 3.44% | 3.92% | 0.63% | 3.37% | 2.42% | 3.66% |
| RBC | 1.44% | 1.76% | 2.88% | 2.31% | 0.82% | 2.43% | 2.14% | 2.19% | 1.98% | 1.72% |
| HGB | 3.10% | 1.68% | 0.72% | 0.90% | 1.14% | 3.30% | 2.73% | 1.77% | 2.83% | 2.87% |
| HCT | 2.04% | 2.30% | 2.51% | 2.75% | 1.13% | 0.98% | 1.41% | 1.08% | 2.80% | 3.00% |
| MCV | 2.78% | 0.92% | 0.81% | 1.10% | 1.95% | 2.62% | 0.68% | 1.96% | 2.23% | 2.90% |
| PLT | 2.77% | 1.33% | 3.36% | 1.16% | 1.04% | 1.13% | 1.85% | 0.89% | 2.59% | 2.46% |
表3 实施例2测值CV值
| 猫科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 3.55% | 1.79% | 2.86% | 1.94% | 3.18% | 2.82% | 2.51% | 0.76% | 3.08% | 3.27% |
| NEU# | 1.68% | 1.66% | 3.90% | 1.19% | 3.55% | 0.66% | 2.69% | 3.38% | 3.98% | 1.37% |
| Lym# | 0.86% | 2.94% | 2.31% | 2.33% | 3.27% | 1.04% | 2.46% | 2.81% | 1.43% | 3.97% |
| Mon# | 3.73% | 1.89% | 1.33% | 2.44% | 3.21% | 1.76% | 0.86% | 3.58% | 2.07% | 2.55% |
| Eos# | 2.28% | 1.30% | 3.11% | 0.62% | 2.16% | 2.64% | 2.82% | 3.51% | 2.35% | 2.71% |
| Bas# | 0.00% | 2.17% | 0.00% | 1.99% | 0.00% | 0.00% | 0.00% | 2.53% | 0.00% | 2.55% |
| RBC | 2.28% | 1.30% | 0.71% | 2.31% | 2.56% | 1.27% | 2.25% | 1.50% | 1.05% | 1.10% |
| HGB | 1.56% | 2.20% | 1.44% | 2.92% | 1.26% | 2.03% | 0.63% | 0.95% | 0.84% | 0.93% |
| HCT | 2.90% | 2.60% | 2.03% | 1.11% | 1.67% | 2.47% | 1.75% | 2.09% | 0.79% | 0.98% |
| MCV | 2.15% | 0.92% | 2.54% | 2.53% | 0.53% | 2.09% | 1.67% | 1.49% | 1.13% | 2.03% |
| PLT | 1.46% | 2.42% | 0.80% | 1.95% | 1.37% | 2.99% | 3.76% | 3.77% | 2.25% | 3.10% |
| 犬科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 0.89% | 2.45% | 3.08% | 2.59% | 1.48% | 3.58% | 1.53% | 3.51% | 0.51% | 0.76% |
| NEU# | 3.39% | 0.64% | 2.93% | 2.85% | 1.32% | 0.99% | 3.14% | 1.91% | 2.06% | 2.87% |
| Lym# | 2.72% | 3.68% | 3.36% | 3.62% | 3.42% | 2.61% | 0.96% | 2.14% | 2.21% | 1.44% |
| Mon# | 2.28% | 3.42% | 2.43% | 1.40% | 1.32% | 2.83% | 1.93% | 1.52% | 2.36% | 2.80% |
| Eos# | 2.45% | 1.60% | 1.36% | 1.01% | 2.59% | 3.77% | 2.71% | 1.17% | 3.73% | 1.15% |
| Bas# | 2.63% | 2.72% | 0.00% | 0.00% | 0.00% | 0.00% | 2.59% | 0.00% | 3.68% | 1.00% |
| RBC | 1.56% | 1.81% | 1.04% | 1.16% | 1.04% | 1.25% | 0.72% | 2.36% | 1.99% | 2.91% |
| HGB | 2.27% | 0.70% | 1.96% | 2.77% | 2.23% | 1.71% | 0.62% | 0.64% | 2.05% | 0.92% |
| HCT | 0.98% | 0.97% | 0.64% | 2.60% | 2.76% | 2.17% | 2.65% | 2.35% | 2.36% | 1.13% |
| MCV | 1.52% | 2.99% | 0.69% | 1.32% | 0.97% | 1.93% | 2.10% | 1.53% | 2.65% | 2.96% |
| PLT | 1.07% | 1.79% | 3.01% | 2.42% | 2.64% | 0.76% | 2.10% | 3.40% | 3.05% | 1.91% |
| 马样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 1.23% | 2.79% | 2.33% | 1.85% | 3.85% | 3.62% | 1.49% | 1.59% | 0.68% | 2.96% |
| NEU# | 1.44% | 1.59% | 1.13% | 0.69% | 1.01% | 3.49% | 3.07% | 3.78% | 3.22% | 0.95% |
| Lym# | 0.64% | 2.66% | 2.71% | 2.36% | 0.80% | 3.93% | 3.59% | 3.04% | 3.89% | 1.69% |
| Mon# | 3.08% | 1.98% | 1.32% | 3.52% | 0.56% | 2.70% | 3.45% | 2.34% | 1.05% | 3.03% |
| Eos# | 2.84% | 2.38% | 1.13% | 1.43% | 2.86% | 2.16% | 0.84% | 1.90% | 1.02% | 2.08% |
| Bas# | 3.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.91% | 3.64% | 0.00% | 0.00% |
| RBC | 1.92% | 1.37% | 1.40% | 1.49% | 1.59% | 1.76% | 1.38% | 1.42% | 2.90% | 2.58% |
| HGB | 2.60% | 1.57% | 3.17% | 0.65% | 0.78% | 1.55% | 0.91% | 1.80% | 3.50% | 1.56% |
| HCT | 2.66% | 1.10% | 2.46% | 1.09% | 1.35% | 1.81% | 0.74% | 0.50% | 0.59% | 2.70% |
| MCV | 2.87% | 1.41% | 1.15% | 1.71% | 2.69% | 2.59% | 1.18% | 2.53% | 2.15% | 1.29% |
| PLT | 3.63% | 0.83% | 2.68% | 2.06% | 1.26% | 1.72% | 3.23% | 0.75% | 2.78% | 1.07% |
表4 实施例2测值准确性相对偏差
| 猫科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 2.44% | 3.80% | 3.92% | 0.52% | 2.32% | 1.66% | 2.57% | 1.49% | 0.83% | 1.42% |
| NEU# | 2.53% | 1.47% | 2.39% | 2.54% | 1.79% | 2.04% | 3.89% | 2.12% | 3.86% | 2.16% |
| Lym# | 0.95% | 2.71% | 1.23% | 3.73% | 3.02% | 3.96% | 0.93% | 3.73% | 1.03% | 3.82% |
| Mon# | 2.97% | 1.24% | 1.92% | 0.93% | 2.51% | 3.91% | 3.86% | 2.53% | 3.59% | 2.66% |
| Eos# | 0.76% | 3.03% | 0.94% | 2.63% | 1.05% | 3.40% | 1.44% | 0.82% | 2.64% | 3.81% |
| Bas# | 0.00% | 1.78% | 0.00% | 2.32% | 0.00% | 3.49% | 0.00% | 0.00% | 0.00% | 2.34% |
| RBC | 2.25% | 2.18% | 2.28% | 0.78% | 0.53% | 2.39% | 2.81% | 2.45% | 1.72% | 2.11% |
| HGB | 1.09% | 1.47% | 0.97% | 2.17% | 2.27% | 1.34% | 0.60% | 1.87% | 3.11% | 2.68% |
| HCT | 1.91% | 1.01% | 1.42% | 2.49% | 2.22% | 1.02% | 0.57% | 1.06% | 0.66% | 2.98% |
| MCV | 1.74% | 1.99% | 1.88% | 1.21% | 2.91% | 1.52% | 0.62% | 0.56% | 2.22% | 1.81% |
| PLT | 1.71% | 0.66% | 2.62% | 2.97% | 0.89% | 1.61% | 1.93% | 3.28% | 1.47% | 0.59% |
| 犬科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 2.20% | 3.02% | 1.15% | 1.27% | 0.88% | 2.10% | 2.74% | 2.28% | 3.69% | 2.01% |
| NEU# | 2.00% | 1.02% | 1.05% | 2.09% | 1.37% | 0.96% | 1.40% | 2.36% | 1.06% | 1.04% |
| Lym# | 3.48% | 2.63% | 3.96% | 2.18% | 3.60% | 2.78% | 2.64% | 3.32% | 1.54% | 3.43% |
| Mon# | 3.51% | 2.36% | 3.99% | 3.05% | 1.27% | 2.06% | 0.79% | 3.19% | 3.75% | 2.52% |
| Eos# | 0.56% | 2.00% | 2.48% | 1.84% | 3.30% | 3.89% | 2.39% | 2.37% | 3.00% | 1.26% |
| Bas# | 0.00% | 3.24% | 0.00% | 0.00% | 4.40% | 0.00% | 2.64% | 0.00% | 0.00% | 3.51% |
| RBC | 2.96% | 2.14% | 1.61% | 2.35% | 0.67% | 1.25% | 0.85% | 1.05% | 2.90% | 1.93% |
| HGB | 3.43% | 2.50% | 1.67% | 2.14% | 2.94% | 0.85% | 2.40% | 2.63% | 2.48% | 0.74% |
| HCT | 1.57% | 1.84% | 2.98% | 0.51% | 0.96% | 2.73% | 2.64% | 2.66% | 0.61% | 1.18% |
| MCV | 2.73% | 0.57% | 0.93% | 2.91% | 1.23% | 2.72% | 2.51% | 0.65% | 0.63% | 1.19% |
| PLT | 2.71% | 1.41% | 1.86% | 2.93% | 0.61% | 2.34% | 1.58% | 0.73% | 0.95% | 3.00% |
| 马样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 0.77% | 3.57% | 0.99% | 0.59% | 0.61% | 3.92% | 1.10% | 1.34% | 1.59% | 0.55% |
| NEU# | 1.56% | 1.69% | 1.09% | 2.98% | 3.85% | 1.58% | 2.28% | 1.33% | 0.61% | 3.40% |
| Lym# | 2.10% | 2.00% | 1.91% | 2.37% | 3.73% | 2.00% | 1.00% | 3.34% | 2.78% | 3.44% |
| Mon# | 0.99% | 2.19% | 1.48% | 0.76% | 1.63% | 2.76% | 0.57% | 0.53% | 2.99% | 3.68% |
| Eos# | 2.21% | 1.55% | 2.52% | 0.95% | 2.23% | 0.79% | 2.06% | 1.62% | 2.57% | 3.64% |
| Bas# | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.31% | 1.12% | 0.00% | 0.00% |
| RBC | 1.22% | 2.42% | 1.83% | 0.59% | 2.35% | 2.33% | 0.78% | 1.10% | 2.79% | 2.94% |
| HGB | 1.92% | 0.83% | 2.14% | 0.89% | 2.35% | 1.91% | 2.60% | 0.91% | 0.68% | 2.71% |
| HCT | 0.65% | 2.97% | 1.31% | 2.74% | 2.00% | 2.03% | 2.70% | 2.55% | 0.84% | 1.39% |
| MCV | 1.56% | 1.36% | 1.55% | 0.86% | 2.56% | 2.36% | 2.18% | 2.10% | 2.51% | 0.53% |
| PLT | 1.15% | 3.93% | 1.41% | 2.62% | 3.94% | 3.11% | 0.86% | 2.79% | 0.79% | 0.57% |
表5 实施例3测值CV值
| 猫科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 2.47% | 3.21% | 2.61% | 3.74% | 0.76% | 2.93% | 3.48% | 1.37% | 3.63% | 1.81% |
| NEU# | 2.45% | 2.38% | 0.98% | 3.03% | 3.76% | 3.84% | 0.83% | 1.20% | 3.90% | 1.23% |
| Lym# | 1.91% | 2.26% | 3.85% | 1.86% | 1.06% | 2.90% | 1.59% | 3.42% | 0.82% | 3.55% |
| Mon# | 2.83% | 1.07% | 2.59% | 0.82% | 0.54% | 1.79% | 1.50% | 3.57% | 1.31% | 3.58% |
| Eos# | 0.61% | 2.06% | 1.38% | 0.68% | 2.13% | 2.33% | 2.59% | 2.16% | 0.91% | 2.84% |
| Bas# | 0.00% | 1.09% | 0.00% | 2.86% | 3.58% | 0.00% | 0.00% | 4.00% | 0.00% | 0.92% |
| RBC | 1.12% | 2.22% | 0.83% | 1.57% | 1.04% | 2.47% | 1.27% | 2.96% | 1.23% | 2.06% |
| HGB | 2.59% | 3.43% | 1.26% | 0.73% | 2.87% | 0.68% | 3.10% | 0.55% | 2.89% | 3.02% |
| HCT | 2.73% | 1.62% | 0.70% | 2.04% | 1.02% | 1.87% | 1.09% | 1.12% | 2.83% | 1.65% |
| MCV | 2.00% | 0.87% | 1.70% | 2.49% | 0.59% | 1.75% | 0.80% | 2.24% | 1.97% | 2.17% |
| PLT | 3.83% | 3.27% | 3.83% | 3.31% | 3.60% | 2.67% | 0.69% | 2.17% | 3.01% | 0.58% |
| 犬科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 2.65% | 1.88% | 1.54% | 3.82% | 2.07% | 2.24% | 1.10% | 2.27% | 3.92% | 1.81% |
| NEU# | 3.56% | 3.82% | 0.71% | 3.02% | 2.64% | 1.23% | 3.40% | 0.63% | 1.84% | 3.23% |
| Lym# | 3.41% | 1.03% | 3.70% | 3.64% | 1.04% | 3.83% | 3.66% | 3.03% | 3.11% | 3.04% |
| Mon# | 2.87% | 0.77% | 2.90% | 1.35% | 2.07% | 1.32% | 0.94% | 1.28% | 2.65% | 2.50% |
| Eos# | 2.19% | 0.73% | 3.20% | 2.78% | 2.21% | 1.41% | 1.65% | 2.15% | 2.03% | 3.62% |
| Bas# | 2.23% | 1.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.29% | 2.54% |
| RBC | 1.67% | 2.93% | 1.78% | 1.95% | 2.08% | 0.89% | 0.90% | 2.20% | 2.45% | 2.05% |
| HGB | 1.20% | 2.64% | 1.51% | 2.08% | 0.65% | 1.13% | 1.00% | 2.05% | 2.57% | 2.34% |
| HCT | 0.67% | 2.37% | 1.07% | 2.31% | 1.03% | 2.79% | 2.54% | 1.22% | 2.31% | 1.86% |
| MCV | 1.46% | 1.28% | 2.56% | 2.57% | 1.00% | 2.12% | 0.74% | 1.13% | 1.30% | 2.98% |
| PLT | 3.29% | 3.52% | 3.85% | 1.86% | 3.26% | 3.71% | 2.32% | 2.79% | 2.58% | 0.50% |
| 马样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 0.59% | 3.18% | 0.80% | 2.06% | 1.90% | 1.07% | 0.60% | 0.67% | 1.36% | 1.05% |
| NEU# | 2.38% | 1.61% | 3.14% | 2.94% | 0.89% | 3.43% | 1.62% | 3.05% | 3.35% | 0.68% |
| Lym# | 1.51% | 2.28% | 2.64% | 2.17% | 2.46% | 2.16% | 0.84% | 1.93% | 1.61% | 1.80% |
| Mon# | 1.99% | 0.87% | 3.13% | 3.02% | 1.69% | 1.36% | 3.27% | 3.26% | 2.31% | 2.65% |
| Eos# | 1.73% | 1.69% | 1.23% | 3.12% | 3.74% | 1.37% | 3.74% | 3.55% | 3.39% | 3.86% |
| Bas# | 1.66% | 0.00% | 3.27% | 0.00% | 0.99% | 0.00% | 3.99% | 2.79% | 3.96% | 0.00% |
| RBC | 2.00% | 1.87% | 1.60% | 0.96% | 2.67% | 1.99% | 1.63% | 1.30% | 1.57% | 1.82% |
| HGB | 0.51% | 1.50% | 2.46% | 1.82% | 1.61% | 1.54% | 1.87% | 0.88% | 1.84% | 2.50% |
| HCT | 0.85% | 2.57% | 1.95% | 0.86% | 2.91% | 1.43% | 1.86% | 2.39% | 0.86% | 1.26% |
| MCV | 2.61% | 2.26% | 1.32% | 0.63% | 0.91% | 1.83% | 2.30% | 1.95% | 1.53% | 2.48% |
| PLT | 2.08% | 3.63% | 1.51% | 1.81% | 0.60% | 3.40% | 1.38% | 0.90% | 1.26% | 2.62% |
表6 实施例3测值准确性相对偏差
| 猫科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 0.80% | 3.78% | 2.02% | 3.62% | 1.47% | 2.59% | 2.27% | 2.39% | 1.27% | 0.80% |
| NEU# | 2.67% | 1.36% | 2.41% | 1.01% | 0.95% | 0.82% | 1.06% | 3.35% | 2.30% | 2.04% |
| Lym# | 2.29% | 1.30% | 1.28% | 1.71% | 2.80% | 1.70% | 1.45% | 2.86% | 0.95% | 3.73% |
| Mon# | 3.86% | 1.13% | 0.69% | 3.51% | 3.44% | 0.57% | 2.88% | 1.75% | 3.15% | 3.00% |
| Eos# | 0.51% | 2.96% | 2.68% | 2.95% | 2.19% | 0.65% | 1.14% | 3.56% | 2.80% | 0.97% |
| Bas# | 0.00% | 0.00% | 0.00% | 2.25% | 3.99% | 0.00% | 0.00% | 2.38% | 0.00% | 0.77% |
| RBC | 2.27% | 2.97% | 2.90% | 2.87% | 2.39% | 2.89% | 1.39% | 2.16% | 0.98% | 0.52% |
| HGB | 1.33% | 3.42% | 3.34% | 1.48% | 2.03% | 1.31% | 0.56% | 1.77% | 0.52% | 2.80% |
| HCT | 1.77% | 1.09% | 1.50% | 1.82% | 3.00% | 2.22% | 1.58% | 0.75% | 1.98% | 2.18% |
| MCV | 2.67% | 2.91% | 2.15% | 2.10% | 1.27% | 1.23% | 0.69% | 1.09% | 0.58% | 1.33% |
| PLT | 3.71% | 2.42% | 3.01% | 3.26% | 0.56% | 2.95% | 3.39% | 1.17% | 1.31% | 3.73% |
| 犬科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 1.13% | 1.77% | 2.92% | 1.68% | 2.79% | 3.39% | 3.87% | 1.00% | 2.46% | 2.33% |
| NEU# | 0.87% | 2.75% | 0.55% | 1.61% | 3.01% | 1.92% | 3.11% | 3.32% | 1.81% | 2.74% |
| Lym# | 2.03% | 3.07% | 1.64% | 1.40% | 1.87% | 2.05% | 0.93% | 0.93% | 3.09% | 1.82% |
| Mon# | 3.21% | 1.72% | 1.06% | 3.72% | 2.12% | 2.72% | 3.40% | 2.63% | 2.06% | 2.94% |
| Eos# | 0.89% | 3.96% | 0.95% | 2.21% | 0.91% | 3.00% | 1.97% | 0.56% | 2.01% | 0.64% |
| Bas# | 2.07% | 1.30% | 0.00% | 3.47% | 0.00% | 0.00% | 3.83% | 0.00% | 1.65% | 0.00% |
| RBC | 2.91% | 1.77% | 2.03% | 1.02% | 1.20% | 2.17% | 1.95% | 0.54% | 2.10% | 0.87% |
| HGB | 2.60% | 3.15% | 2.67% | 2.74% | 1.01% | 1.05% | 3.08% | 0.92% | 2.11% | 2.25% |
| HCT | 1.32% | 1.63% | 2.78% | 1.36% | 0.63% | 0.69% | 2.31% | 1.01% | 1.20% | 2.61% |
| MCV | 2.63% | 2.73% | 0.60% | 2.87% | 1.68% | 1.46% | 2.83% | 2.38% | 0.97% | 0.89% |
| PLT | 0.74% | 1.78% | 1.36% | 2.49% | 0.97% | 3.83% | 2.33% | 3.75% | 3.14% | 0.68% |
| 马样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 0.97% | 1.00% | 1.07% | 0.81% | 0.87% | 2.64% | 3.85% | 0.74% | 1.46% | 1.37% |
| NEU# | 2.18% | 0.79% | 1.57% | 0.67% | 3.47% | 1.93% | 1.74% | 1.78% | 1.26% | 3.26% |
| Lym# | 3.91% | 3.57% | 3.80% | 0.79% | 3.66% | 0.80% | 0.61% | 3.72% | 0.79% | 1.47% |
| Mon# | 0.71% | 1.00% | 3.44% | 3.79% | 3.33% | 0.96% | 2.20% | 0.96% | 1.86% | 2.71% |
| Eos# | 0.75% | 2.46% | 2.68% | 0.51% | 3.57% | 2.43% | 1.35% | 3.54% | 1.89% | 3.91% |
| Bas# | 0.00% | 0.00% | 3.02% | 0.00% | 0.00% | 0.00% | 2.11% | 2.42% | 0.00% | 0.00% |
| RBC | 2.63% | 1.04% | 0.73% | 1.26% | 0.87% | 2.37% | 0.72% | 0.67% | 0.69% | 1.04% |
| HGB | 0.89% | 2.57% | 2.41% | 0.93% | 3.19% | 0.63% | 1.53% | 1.58% | 3.00% | 3.36% |
| HCT | 1.01% | 2.38% | 2.05% | 2.31% | 0.56% | 3.00% | 0.59% | 0.69% | 0.92% | 2.66% |
| MCV | 2.35% | 1.70% | 1.00% | 2.72% | 2.68% | 2.63% | 1.53% | 2.10% | 2.95% | 0.66% |
| PLT | 2.33% | 1.47% | 1.14% | 1.78% | 3.56% | 1.97% | 1.51% | 2.92% | 3.86% | 2.60% |
表7 对比例1测值CV值
| 猫科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 4.31% | 6.00% | 6.78% | 7.32% | 4.09% | 5.41% | 5.13% | 7.14% | 3.85% | 6.60% |
| NEU# | 4.65% | 9.88% | 6.37% | 4.83% | 8.07% | 5.69% | 6.53% | 8.05% | 5.61% | 6.22% |
| Lym# | 4.77% | 7.27% | 8.63% | 9.58% | 4.48% | 7.22% | 4.13% | 6.54% | 4.29% | 9.88% |
| Mon# | 3.78% | 6.40% | 7.51% | 8.91% | 5.10% | 6.91% | 4.52% | 3.93% | 8.92% | 9.60% |
| Eos# | 4.25% | 3.69% | 3.60% | 7.89% | 7.55% | 4.48% | 9.41% | 7.38% | 5.78% | 7.07% |
| Bas# | 4.52% | 6.18% | 9.48% | 7.57% | 7.34% | 7.86% | 5.10% | 6.60% | 5.84% | 6.91% |
| RBC | 9.30% | 8.90% | 9.09% | 9.58% | 5.57% | 9.41% | 6.90% | 8.69% | 6.31% | 6.14% |
| HGB | 9.44% | 9.79% | 9.45% | 7.08% | 7.45% | 7.32% | 5.70% | 5.35% | 4.94% | 8.12% |
| HCT | 8.27% | 5.13% | 6.88% | 7.54% | 5.11% | 7.42% | 9.26% | 5.99% | 5.17% | 9.90% |
| MCV | 5.15% | 3.57% | 5.49% | 4.70% | 6.90% | 6.34% | 8.61% | 5.76% | 8.78% | 6.56% |
| PLT | 6.34% | 6.61% | 9.11% | 4.14% | 4.66% | 9.14% | 9.16% | 8.70% | 8.12% | 9.53% |
| 犬科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 7.56% | 5.19% | 5.24% | 9.38% | 6.36% | 7.68% | 8.95% | 4.13% | 4.08% | 7.38% |
| NEU# | 8.07% | 7.00% | 7.58% | 4.96% | 7.71% | 3.84% | 7.88% | 5.17% | 3.94% | 7.59% |
| Lym# | 5.78% | 4.65% | 5.19% | 8.06% | 9.28% | 3.80% | 3.57% | 3.54% | 4.91% | 3.52% |
| Mon# | 6.26% | 7.80% | 8.15% | 8.65% | 9.00% | 6.65% | 3.62% | 6.03% | 5.16% | 8.51% |
| Eos# | 4.33% | 7.78% | 9.21% | 8.05% | 6.54% | 6.41% | 4.99% | 5.15% | 8.14% | 5.58% |
| Bas# | 4.62% | 9.83% | 5.35% | 8.34% | 4.30% | 5.42% | 9.84% | 7.25% | 8.17% | 7.78% |
| RBC | 6.30% | 3.73% | 9.44% | 4.06% | 4.18% | 4.17% | 7.38% | 8.20% | 6.59% | 7.12% |
| HGB | 4.84% | 9.05% | 8.88% | 4.94% | 7.82% | 4.37% | 6.56% | 8.15% | 4.37% | 6.48% |
| HCT | 6.11% | 3.95% | 4.04% | 9.17% | 9.14% | 5.17% | 8.18% | 8.35% | 6.84% | 5.88% |
| MCV | 8.68% | 4.94% | 7.65% | 3.54% | 7.22% | 3.80% | 5.62% | 4.90% | 5.01% | 7.40% |
| PLT | 5.29% | 8.62% | 7.78% | 8.48% | 4.79% | 7.13% | 3.51% | 8.65% | 5.99% | 6.36% |
| 马样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 8.96% | 6.99% | 9.44% | 4.89% | 8.99% | 9.47% | 3.61% | 8.77% | 6.08% | 8.49% |
| NEU# | 3.51% | 5.92% | 5.94% | 6.73% | 4.86% | 6.13% | 6.04% | 8.11% | 4.60% | 5.46% |
| Lym# | 9.83% | 9.19% | 9.69% | 5.71% | 4.19% | 7.87% | 9.33% | 7.26% | 9.91% | 9.06% |
| Mon# | 4.37% | 4.81% | 7.36% | 6.63% | 6.70% | 4.61% | 6.05% | 8.90% | 6.82% | 3.65% |
| Eos# | 9.20% | 8.02% | 4.57% | 5.83% | 4.35% | 8.35% | 4.92% | 9.76% | 6.14% | 3.87% |
| Bas# | 7.39% | 8.12% | 8.63% | 4.05% | 9.50% | 8.56% | 3.53% | 4.17% | 8.80% | 6.93% |
| RBC | 7.81% | 5.99% | 9.53% | 8.85% | 5.31% | 7.17% | 7.84% | 5.90% | 8.92% | 5.80% |
| HGB | 5.26% | 4.85% | 6.52% | 5.24% | 6.52% | 4.56% | 7.18% | 8.51% | 5.08% | 9.27% |
| HCT | 7.41% | 7.05% | 8.43% | 8.00% | 3.90% | 9.15% | 7.61% | 9.64% | 8.23% | 6.78% |
| MCV | 7.48% | 4.88% | 9.70% | 9.48% | 8.11% | 3.76% | 3.90% | 9.80% | 9.23% | 5.96% |
| PLT | 7.35% | 5.82% | 8.74% | 7.41% | 4.63% | 9.14% | 7.33% | 8.85% | 9.49% | 3.93% |
表8 对比例1测值准确性相对偏差
| 猫科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 9.89% | 5.35% | 6.57% | 8.29% | 8.08% | 9.08% | 8.96% | 9.37% | 9.89% | 7.41% |
| NEU# | 6.28% | 6.68% | 8.28% | 7.77% | 5.35% | 4.71% | 7.79% | 6.28% | 5.95% | 3.61% |
| Lym# | 4.07% | 4.65% | 5.45% | 4.12% | 9.43% | 9.36% | 9.53% | 5.20% | 5.29% | 9.18% |
| Mon# | 6.29% | 7.26% | 6.15% | 9.34% | 6.26% | 9.43% | 8.27% | 6.70% | 4.41% | 3.93% |
| Eos# | 7.12% | 9.72% | 7.46% | 4.13% | 7.44% | 7.29% | 5.48% | 9.61% | 4.09% | 9.32% |
| Bas# | 9.45% | 6.64% | 9.00% | 7.83% | 8.18% | 9.31% | 8.39% | 4.57% | 7.25% | 9.04% |
| RBC | 4.76% | 9.96% | 5.81% | 9.87% | 5.86% | 9.18% | 6.21% | 8.35% | 3.79% | 4.27% |
| HGB | 3.72% | 4.49% | 7.32% | 4.43% | 5.19% | 6.77% | 8.28% | 8.27% | 5.03% | 4.32% |
| HCT | 9.28% | 8.30% | 4.75% | 4.63% | 6.34% | 4.31% | 5.50% | 9.76% | 8.51% | 7.50% |
| MCV | 9.38% | 7.50% | 9.90% | 4.88% | 5.15% | 7.47% | 7.53% | 4.68% | 4.29% | 7.78% |
| PLT | 8.76% | 7.04% | 8.92% | 7.15% | 7.23% | 9.35% | 8.16% | 9.12% | 9.83% | 5.79% |
| 犬科样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 5.11% | 3.72% | 6.21% | 9.57% | 3.65% | 8.68% | 9.95% | 5.35% | 8.01% | 7.13% |
| NEU# | 8.88% | 3.94% | 7.80% | 8.28% | 4.98% | 5.31% | 5.07% | 6.87% | 5.37% | 7.94% |
| Lym# | 9.87% | 7.02% | 5.48% | 3.75% | 9.38% | 7.00% | 3.86% | 4.33% | 5.73% | 7.92% |
| Mon# | 8.57% | 4.27% | 8.89% | 8.11% | 3.85% | 6.43% | 5.92% | 7.45% | 9.69% | 9.03% |
| Eos# | 5.57% | 7.27% | 6.84% | 4.13% | 3.71% | 5.02% | 4.78% | 8.79% | 5.11% | 8.04% |
| Bas# | 9.58% | 4.06% | 3.57% | 9.02% | 4.22% | 4.03% | 9.50% | 4.06% | 9.00% | 4.70% |
| RBC | 6.37% | 7.41% | 4.57% | 6.13% | 9.85% | 5.56% | 7.74% | 6.48% | 7.31% | 3.84% |
| HGB | 5.61% | 6.68% | 4.22% | 8.16% | 8.49% | 4.01% | 3.62% | 5.02% | 9.31% | 4.77% |
| HCT | 9.11% | 4.60% | 5.28% | 8.90% | 8.46% | 6.50% | 9.70% | 5.04% | 8.88% | 5.36% |
| MCV | 3.57% | 6.90% | 4.55% | 5.28% | 3.96% | 6.79% | 7.94% | 4.87% | 8.79% | 6.28% |
| PLT | 3.54% | 8.40% | 4.59% | 8.81% | 7.21% | 6.32% | 7.30% | 5.19% | 4.52% | 6.16% |
| 马样本 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| WBC | 8.35% | 5.64% | 9.83% | 8.38% | 7.45% | 8.15% | 5.48% | 7.17% | 7.36% | 4.90% |
| NEU# | 6.38% | 5.77% | 6.93% | 9.80% | 5.57% | 7.24% | 4.39% | 8.43% | 4.88% | 9.89% |
| Lym# | 6.90% | 5.17% | 6.53% | 6.70% | 9.62% | 6.57% | 6.53% | 8.96% | 9.46% | 6.37% |
| Mon# | 3.87% | 8.56% | 4.14% | 8.79% | 5.38% | 4.97% | 6.20% | 8.62% | 3.99% | 5.25% |
| Eos# | 6.97% | 7.38% | 3.69% | 8.36% | 4.41% | 9.74% | 7.93% | 8.31% | 6.77% | 8.51% |
| Bas# | 9.62% | 6.71% | 6.05% | 7.28% | 8.13% | 4.51% | 5.32% | 5.97% | 4.19% | 3.95% |
| RBC | 5.71% | 6.89% | 6.22% | 7.70% | 6.61% | 8.87% | 8.28% | 9.33% | 8.01% | 9.87% |
| HGB | 6.69% | 8.24% | 9.55% | 7.49% | 6.31% | 9.69% | 4.14% | 7.29% | 7.72% | 5.16% |
| HCT | 4.97% | 5.38% | 6.81% | 4.94% | 5.60% | 6.16% | 7.91% | 3.65% | 5.24% | 9.93% |
| MCV | 3.97% | 7.39% | 4.28% | 7.80% | 8.60% | 9.93% | 7.28% | 7.80% | 6.00% | 8.17% |
| PLT | 6.42% | 5.55% | 6.77% | 6.83% | 4.74% | 6.97% | 9.92% | 3.53% | 4.81% | 6.40% |
使用本发明的五分类兽用血细胞检测试剂测试30支全血样本后，测值CV值RBC、HCT和MCV均小于3.00%，HGB小于3.5%，试剂测试稳定性良好，其与迈瑞测值对比后准确性相对偏差均很小，同样能做到RBC、HCT和MCV小于3.00%，HGB小于3.5%，PLT小于4.00%，试剂测试准确性良好。
对比例1与实施例1~3的主要区别在于：①所用的稀释液采用了磷酸盐缓冲液，且稀释液中渗透压调节剂的浓度与实施例1~3相比差异较大；②稀释液中渗透压调节剂的浓度较大；③第一溶血剂中非离子表面活性剂浓度较高；④第二溶血剂中未添加十二烷基三甲基氯化铵或者十二烷基三甲基溴化铵，且添加了较高含量的第三防腐剂。采用对比例1进行测试的测值CV值和相对偏差均较大，由此可见，采用磷酸盐缓冲液、稀释液中较高的渗透压调节剂浓度、第一溶血剂中较高的非离子表面活性剂浓度、第二溶血剂中未添加溶解红细胞的十二烷基三甲基氯化铵或者十二烷基三甲基溴化铵均会对兽用五分类血细胞检测产生不利影响。
以上仅为本发明的实施例而已，并不用于限制本发明，凡在本发明的精神和原则之内，所做的任何修改、等同替换、改进等，均包含在申请待批的本发明的权利要求范围之内。
Claims (10)
1.一种兽用五分类血细胞检测试剂，其特征在于，包括：稀释液、第一溶血剂和第二溶血剂；
所述稀释液包括：第一缓冲液50～100 mmol/L、渗透压调节剂2.2～6.2 g/L、抗凝剂0.05～0.5 g/L、第一防腐剂0.025～0.5 g/L；
所述第一溶血剂包括：非离子表面活性剂0.05～2 g/L、第一阳离子表面活性剂0.05～6.75 g/L、第二缓冲液50～100 mmol/L和第二防腐剂0.02～1 g/L；
所述第二溶血剂包括：第二阳离子表面活性剂0.2～10 g/L、第三缓冲液50～100mmol/L和第三防腐剂0.02～0.5 g/L。
2.根据权利要求1所述的一种兽用五分类血细胞检测试剂，其特征在于，所述第一缓冲液为Tris-Tris盐酸盐缓冲液，所述Tris-Tris盐酸盐缓冲液包括三羟甲基氨基甲烷和三羟甲基氨基甲烷盐酸盐。
3.根据权利要求1所述的一种兽用五分类血细胞检测试剂，其特征在于，所述渗透压调节剂为氯化钠、氯化钾、硫酸钠中的至少一种。
4.根据权利要求1所述的一种兽用五分类血细胞检测试剂，其特征在于，所述抗凝剂为EDTA·2K、EDTA·2Na、枸橼酸钠中的至少一种。
5.根据权利要求1所述的一种兽用五分类血细胞检测试剂，其特征在于，所述第一防腐剂为Proclin150、Proclin300、庆大霉素、BIT-10、SPT中的至少一种。
6.根据权利要求1所述的一种兽用五分类血细胞检测试剂，其特征在于，所述非离子表面活性剂为AEO-10、吐温60、吐温80和聚乙二醇200中的至少一种；所述第一阳离子表面活性剂为十二烷基三甲基溴化铵、十六烷基三甲基氯化铵中的至少一种。
7.根据权利要求1所述的一种兽用五分类血细胞检测试剂，其特征在于，所述第二缓冲液为柠檬酸和柠檬酸钠或者柠檬酸和磷酸氢二钠。
8.根据权利要求1所述的一种兽用五分类血细胞检测试剂，其特征在于，所述第二防腐剂为甲醇或者Proclin300；所述第三防腐剂为甲醇。
9.根据权利要求1所述的一种兽用五分类血细胞检测试剂，其特征在于，所述第二阳离子表面活性剂为十二烷基三甲基氯化铵、十六烷基三甲基氯化铵、十二烷基三甲基溴化铵、十六烷基三甲基溴化铵中的至少一种。
10.根据权利要求1所述的一种兽用五分类血细胞检测试剂，其特征在于，所述第三缓冲液为草酸和草酸钾或者草酸和磷酸氢二钾。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311644489.1A CN117665295A (zh) | 2023-12-04 | 2023-12-04 | 一种兽用五分类血细胞检测试剂及制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311644489.1A CN117665295A (zh) | 2023-12-04 | 2023-12-04 | 一种兽用五分类血细胞检测试剂及制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117665295A true CN117665295A (zh) | 2024-03-08 |
Family
ID=90083911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311644489.1A Pending CN117665295A (zh) | 2023-12-04 | 2023-12-04 | 一种兽用五分类血细胞检测试剂及制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117665295A (zh) |
-
2023
- 2023-12-04 CN CN202311644489.1A patent/CN117665295A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5486477A (en) | Reagent system for improved multiple species blood analysis | |
| CA1117401A (en) | Multi-purpose blood diluent for use in electronic blood analysis instrumentation | |
| CA1222679A (en) | Reagent for combined diluting and lysing whole blood | |
| EP1000356B1 (en) | Blood diluent | |
| US4219440A (en) | Multiple analysis hematology reference control reagent and method of making the same | |
| US5227304A (en) | Method for counting whole blood diluent and detergent reagent system | |
| US7285417B2 (en) | Reference control containing a nucleated red blood cell component | |
| EP1810025B1 (en) | Lysing reagent for simultaneous enumeration of different types of blood cells in a blood sample | |
| FI93658B (fi) | Reagenssi ja sitä käyttävä menetelmä vähintään yhden leukosyyttialapopulaation määrittämiseksi kokoverestä automaattisella virtaussolulaskennalla | |
| JP4889730B2 (ja) | シアニドを含まない溶解試薬組成物；ならびにヘモグロビンおよび白血球の測定のための使用の方法 | |
| US6632676B1 (en) | Multi-purpose reagent system and method for enumeration of red blood cells, white blood cells and thrombocytes and differential determination of white blood cells | |
| US4506018A (en) | Blood diluent | |
| US20040241769A1 (en) | Multi-purpose reagent system and method for enumeration of red blood cells, white blood cells and thrombocytes and differential determination of white blood cells | |
| JP2008032750A (ja) | ヘモグロビン及び細胞分析のためのシアン化物不含溶解試薬組成物及び方法 | |
| CN101451931B (zh) | 血液稀释液及其使用方法 | |
| CN101246158B (zh) | 测定血细胞中白细胞的溶血剂 | |
| CN1115561C (zh) | 一种血液分析计数仪用稀释液和清洗液 | |
| CN108872225A (zh) | 一种检测动物血球的检测试剂及检测方法 | |
| EP1376135B1 (en) | Automated method and reagent therefor for assaying body fluid samples such as cerebrospinal fluid | |
| Stevens et al. | Hematologic, blood gas, blood chemistry, and serum mineral values for a sample of clinically healthy adult goats | |
| CN117665295A (zh) | 一种兽用五分类血细胞检测试剂及制备方法 | |
| EP1682865B1 (en) | Method of using a reference control composition for measurement of nucleated red blood cells | |
| US4244837A (en) | Multi-purpose blood diluent for use in electronic blood analysis instrumentation | |
| Weiser | Comparison of Two Automated Multi‐Channel Blood Cell Counting Systems for Analysis of Blood of Common Domestic Animals | |
| CN112305210B (zh) | 一种兽用三分类血细胞分析试剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |